Atara Biotherapeutics has received a green light to enroll U.S. patients into a Phase 1 trial of ATA188 for progressive or relapsing-remitting multiple sclerosis (MS).
The study was initially launched ... Read more
Researchers, working with an animal model of multiple sclerosis (MS), discovered that oral treatment with a synthesized plant peptide, known as cyclotide, halted the progression of clinical symptoms without ... Read more
Opexa Therapeutics, Inc., announced that it has been named one of the “Top Projects to Watch” for the third consecutive year. A panel of independent experts recognized the biopharmaceutical company for its ... Read more
Researchers at Monash University and the MIMR-PHI Institute of Medical Research in Australia recently proposed that specific human stem cells with immunomodulatory properties represent a new promising therapeutic strategy ... Read more
A new study recently published in the journal Science Translational Medicine revealed a key difference in immune T cells between multiple sclerosis (MS) patients and healthy individuals. The study ... Read more